HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study.

Brenda Bongaerts,Oliver Kuss,Fabrice Bonnet,Hungta Chen,Andrew Cooper,Peter Fenici,Marilia B Gomes,Niklas Hammar,Linong Ji,Kamlesh Khunti,Jesús Medina,Antonio Nicolucci,Marina V Shestakova,Hirotaka Watada,Wolfgang Rathmann

Diabetes, obesity & metabolism（2023）

引用 0|浏览22

暂无评分

摘要

Most people receiving second-line glucose-lowering treatment in this global cohort achieved stable good or highly improved long-term glycaemic control. One-fifth of participants showed moderate or poor glycaemic control during follow-up. Further large-scale studies are required to characterize possible factors associated with patterns of glycaemic control to inform personalized diabetes treatment.

查看译文

关键词

glucose-lowering drug,glycaemic control,observational study,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要